Please assess the completion status of the following clinical trial:

Trial Title: AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females of non-childbearing potential~* Age ≥18 to ≤75~* Body Mass Index (BMI) ≥18 to ≤35 kg/m2~* CAD patients, here defined as:~ACS 7-28 days prior to study randomization (ACS defined as STEMI, non STEMI event documented by Electrocardiogram (ECG), cardiac enzymes \[troponin\] and angiogram) Provision of signed and dated, written informed consent prior to any study specific procedures~Exclusion Criteria:~* Uncontrolled Type 1 or Type 2 diabetes defined as haemoglobin A1c (HbA1c) Diabetes~* Control and Complications Trial (DCCT)\> 9% or International Federation of Clinical Chemistry (IFCC) \>74.9 mmol/mol~* Patients with atrial fibrillation (chronic or current) or history of ventricular tachycardia requiring therapy for termination, or symptomatic sustained ventricular tachycardia or sick sinus syndrome or Atrioventricular blockage degree 2-3~* Prior coronary artery by-pass graft (Coronary artery bypass grafting) to Left Anterior Descending artery (LAD)~* Left ventricle ejection fraction \< 30%~* Unacceptable level of angina despite maximal medical therapy or unstable angina at entry~* Canadian Cardiovascular Society (CCS) ≥ 3 (Visit 1 or Visit 2)~* Stroke within the previous 6 months from ACS or ongoing treatment with Persantin or Asasantin~* Chronic use of anticoagulants on therapeutic dose (not including thrombosis prophylaxis) during the study~* Planned additional cardiac intervention (e.g., Percutaneous coronary intervention (PCI), Coronary artery bypass grafting (CABG) within next 6 months~* New York Heart Association (NYHA) class III-IV heart failure or decompensated heart failure at discharge or hospitalization for exacerbation of chronic heart failure within the previous 3 months from ACS~* Previously known severe renal disease (Chronic Kidney Disease (CKD) stage 4 or 5) or previously known creatinine clearance calculated by Cockcroft Gault equation \<30 ml/min\*m2~* Known allergy to adenosine and mannitol, or experience of previous adverse effects of adenosine stress testing.~* Participation in another interventional clinical study with an investigational pharmaceutical product during the last 3 months also including drug eluting stents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- AZD5718 Dose A (Type: EXPERIMENTAL): AZD5718 Dose A once daily
- AZD5718 Dose B (Type: EXPERIMENTAL): AZD5718 Dose B once daily
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).